---
aliases: [2158.HK, 医渡科技]
---
#actor #ai #healthcare #china #public

**Yidu Tech** — [[Healthcare]] AI platform. Public (2158.HK). 6B+ medical records processed, 4,000 hospitals covered. Still unprofitable but growing.

---

## Why Yidu Tech matters

Pioneer in Chinese healthcare AI, betting on demographic pressure:

| Metric | Value |
|--------|-------|
| Ticker | 2158.HK |
| Market cap | HK$6.3B (~$800M) |
| Stock price | HK$5.91 (Jan 2026) |
| 1Y return | +124% |
| EBITDA | -HK$346M |
| Employees | ~900 |

---

## Core thesis

Founder Gong Yingying's framing: traditional healthcare supply chains unsustainable under aging peak expected by 2030. AI-powered efficiency is the only path to scale.

**Demographic bet:** [[China]]'s healthcare system must do more with less. Yidu provides the intelligence layer.

---

## Technology

**YiduCore** — unified data architecture:

| Metric | Value |
|--------|-------|
| Medical records processed | 6B+ authorized |
| Hospital coverage | 4,000 hospitals |
| Research deployments | 110+ institutions |
| AI platform deployments | 30+ hospitals |

Built comprehensive disease knowledge graph and 20+ specialized disease datasets with clinicians.

---

## Business segments

| Segment | Description |
|---------|-------------|
| Big Data Platform | Hospital data infrastructure |
| [[Life Sciences]] Solutions | Pharma/research support |
| Health Management | Patient-facing solutions |

---

## 2025 Product launches

**Clinical Copilot:**
- AI diagnosis and treatment assistant
- Served 26,000 patients (Feb-Jun 2025)
- Built on AI Middleware Platform

**CACA Guidelines Assistant:**
- Cancer treatment AI (with Beijing Cancer Hospital)
- Integrates DeepSeek + YiduCore
- Maps to [[China]]'s cancer diagnosis guidelines

**Eywa 5.0:**
- Next-gen data center platform
- Launched at CHIMA 2025 (May)

---

## Geographic expansion

| Market | Status |
|--------|--------|
| [[China]] | Core (4,000 hospitals) |
| Brunei | JV with Ministry of Health (nationwide AI platform) |
| Singapore | Ministry of Health home-based care |
| [[Japan]] | Operations established |
| USA | Operations established |

Brunei deal: EVYD joint venture building nationwide disease screening, health assessments, continuous monitoring.

---

## Financials

**Still unprofitable:**

| Metric | Value |
|--------|-------|
| Revenue trend | +14% YoY (recent) |
| 3Y revenue | -26% |
| EBITDA margin | -41% |
| EPS forecast | -CNY 0.15 (next FY) |
| Dividend | None |

Revenue decline over 3 years despite recent uptick. Path to profitability unclear.

---

## Stock performance

| Metric | Value |
|--------|-------|
| Current price | HK$5.91 |
| 52W range | HK$2.82 - HK$5.91 |
| All-time high | HK$69.80 (Jan 2021) |
| All-time low | HK$2.82 (Sep 2024) |
| 1Y return | +124% |
| YTD | +82% |

**Down 91% from IPO high** but strong recent momentum.

Analyst consensus: Strong Buy, avg target HK$7.79 (range 6.82-10.50).

---

## Investment case

**Bull:**
- AI healthcare addressable market enormous
- Government partnerships (Brunei, Singapore)
- 6B records = data moat
- Demographic tailwinds (aging [[China]])
- Stock up 124% off lows

**Bear:**
- Still unprofitable after decade
- 91% below IPO high
- [[China]] healthcare policy risk
- Revenue declined 26% over 3 years
- Competition from tech giants ([[Alibaba]] Health, [[Tencent]])

---

## Leadership

| Role | Name |
|------|------|
| Founder & Chairwoman | Gong Yingying (Gong Rujing) |
| Founded | ~2014 |
| HQ | Beijing |

Gong is a [[World Economic Forum]] Young Global Leader.

---

## Related

- [[China healthcare]] — domestic market dynamics
- [[DeepSeek]] — partner (CACA Guidelines integration)
- [[Alibaba Health]] — competitor
- [[Healthcare AI]] — industry concept

